# Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

Source: https://onco.cc/trials/nct03990896/  
OnCo record `nct03990896` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This study tests a PARP inhibitor; the registry reports that it is recruiting.

## Summary

The registry lists NCT03990896 as recruiting, last updated 2026-05-06. Enrolment is 30 planned participants, an estimate. Interventions: Talazoparib. Primary measures include Median Progression Free Survival. No results are posted in the registry; this does not exclude separate publications.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-06
- Registry id: NCT03990896
- Phase: 2
- Setting: Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
- Sponsor: Massachusetts General Hospital

## Sources

- ClinicalTrials.gov NCT03990896: https://clinicaltrials.gov/study/NCT03990896

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- targets: [PARP](https://onco.cc/targets/parp/)
- drugs: [Talazoparib](https://onco.cc/drugs/talazoparib/)

---
JSON: https://onco.cc/api/v1/entities/nct03990896.json